UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 9, 2009
Mymetics Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State of other jurisdiction
of incorporation)
|
|
000-25132
(Commission
File Number)
|
|
25-1741849
(IRS Employer
Identification No.) |
| |
|
|
14, rue de la Colombiere
1260 Nyon, Switzerland
(Address of principal executive offices)
|
|
NA
(Zip Code) |
Registrant’s telephone number, including area code: +011 41 22 363 13 10
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
On March 9, 2009 Marc Girard resigned from his position as Head of Vaccine Development of the
Registrant (“Mymetics”). Mr. Girard resigned for reasons of health and time constraints as a
result of his work with various international entities focused on addressing global health
concerns, including the World Health Organization. Mr. Girard’s duties will be assumed by
Mymetics’ CSO, Sylvain Fleury. Mr. Girard will continue to assist Mymetics with development of its
vaccines in his role as a consultant to the company.
- 2 -